Oakdale GroupADHD & autism assessment, waits & prices
Prescribes medication — Adults & childrenOakdale Group reviewsCQC regulatory status
About CQC status: The Care Quality Commission (CQC) is England's independent regulator of health and social care. Regulation is expanding to cover all ADHD and autism assessment providers. Some assessment-only services were not required to register in the past, and newer registrations are often not yet rated. "Not confirmed" means we don't hold CQC details for that provider — not that anything is wrong. What the Fonagy Review means for regulation
hybrid ~78 week wait
Neurodevelopmental assessment service (ADHD and autism) for adults and children. NHS Right to Choose pathway available — long waits (52–78 weeks per ADHD UK).
Are you Oakdale Group? Claim this listing to manage your prices, wait times and review responses.
Oakdale Group at a glance
- Published wait
- 78 weeks
- NHS Right to Choose
- Yes — NHS-funded via GP referral (accepting referrals)
- Adult ADHD assessment
- Not published
- Post-assessment care
- from £1,490
- Shared care
- sometimes
- CQC
- CQC status: not confirmed
- Format
- hybrid
What the evidence says
What it really costs
- Assessment (one-off)
- Cost not published by this provider
- Titration (one-off)
- Cost not published by this provider
- Ongoing care (per year)
- Cost not published by this provider
Not enough public pricing to estimate.
+ Medication — extra, varies by pharmacy
Shared care sometimes — worth asking
Price check date not published — confirm with the provider. Not medical advice.
Oakdale Group waiting times
Published 78-week wait as of 29 September 2026. Waits move frequently — confirm directly before referring.
As a Right to Choose provider, Oakdale Group's NHS-funded wait can differ from its private wait, and ICB funding caps can pause new referrals mid-year.
Oakdale Group and NHS Right to Choose
Oakdale Group holds an NHS contract, so a patient registered with a GP in England can ask to be referred here at NHS expense rather than paying privately. The same clinical standards apply as any NHS ADHD pathway — the difference is who pays and how long you wait.
Oakdale Group is currently accepting Right to Choose referrals.
Read the Right to Choose guideOakdale Group prices
Latest published prices. Always verify on the provider's own website before booking.
Assessed by: Consultant psychiatrist · Clinical psychologist · ADHD specialist nurse
Follow-up and reassessment tiers are in Oakdale Group's full price list below.
ADHD adult assessment
—
ADHD child assessment
—
Autism adult assessment
—
Autism child assessment
—
Follow-up
—
Treatment / month
£150
Post-assessment & ongoing care
£1,490
Titration: Adult £1490, Child £1795. Optional 6-month review package £900. Shared care provider fee £300/year. ECG £75. Self-funded ongoing prescriptions £150/month.
Price not published — confirm with provider — where a price is shown as “—”. Prices last checked 26 September 2026.
Listing details
- Categories
- adhdautismcombined
- Format
- hybrid
- Wait time
- ~78 weeks
- NHS shared care
- sometimes
- Sees under-18s
- Yes
- Last verified
- 16 May 2026
Locations served
- UK-wide
- Online
Why patients pick Oakdale Group
- Assesses children as well as adults.
Things to check
- Shared-care handover only happens in some cases — confirm in writing before booking.
- Wait time is on the longer side — others in the comparison are faster.
- Always check current pricing on Oakdale Group's own website before booking; published fees can change.
Oakdale Group — frequently asked questions
Oakdale Group reviews
No external review score on file yet — see our review policy.
Patient reviews of Oakdale Group
Verified by email confirmation. Independent — providers cannot edit or remove reviews.
No verified reviews yet
Have you been a patient of Oakdale Group? You'd be the first to help others by sharing your experience.
Patients also compared
Same category · organic selection
Compare Oakdale Group with similar providers
See how Oakdale Group stacks up on price, wait time and shared care against the rest of the UK private market.